Nephrology

Empagliflozin reduces risk of progression in at-risk patients with chronic kidney disease

Treatment with empagliflozin therapy led to a lower risk of progression of kidney disease or death from cardiovascular in patients with chronic kidney disease who were at risk for disease progression compared with placebo, according to trial results published in The New England Journal of Medicine. EMPA-KIDNEY was the largest...